Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. PCME Classification
2.3. Statistical Analyses
3. Results
3.1. PCME Incidence
3.2. Clinical Outcomes according to the PCME Classification
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Financial Disclosures
References
- Munk, M.R.; Jampol, L.M.; Simader, C.; Huf, W.; Mittermüller, T.J.; Jaffe, G.J.; Schmidt-Erfurth, U. Differentiation of diabetic macular edema from pseudophakic cystoid macular edema by spectral-domain optical coherence tomography. Investig. Opthalmol. Vis. Sci. 2015, 56, 6724. [Google Scholar] [CrossRef] [PubMed]
- Shields, M.; Adler, P.A.; Fuzzard, D.R.; Chalasani, R.; Teong, J.M. A case of acute bilateral irvine-gass syndrome following uncomplicated phacoemulsification, demonstrated with optical coherence tomography. Case Rep. Ophthalmol. 2015, 6, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Chu, C.J.; Johnston, R.L.; Buscombe, C.; Sallam, A.B.; Mohamed, Q.; Yang, Y.C.; Information, P.E.K.F.C. Risk factors and incidence of macular edema after cataract surgery. Ophthalmology 2016, 123, 316–323. [Google Scholar] [CrossRef] [PubMed]
- Degenring, R.F.; Vey, S.; Kamppeter, B.; Budde, W.M.; Jonas, J.B.; Sauder, G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 245, 18–23. [Google Scholar] [CrossRef]
- Rossetti, L.; Autelitano, A. Cystoid macular edema following cataract surgery. Curr. Opin. Ophthalmol. 2000, 11, 65–72. [Google Scholar] [CrossRef]
- Johnson, M.W. Etiology and treatment of macular edema. Am. J. Ophthalmol. 2009, 147, 11–21.e1. [Google Scholar] [CrossRef]
- McCafferty, S.; Harris, A.; Kew, C.; Kassm, T.; Lane, L.; Levine, J.; Raven, M. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol. 2017, 17, 16. [Google Scholar] [CrossRef]
- Ylinen, P.; Laine, I.; Lindholm, J.-M.; Tuuminen, R. Poor glycemic control as a risk factor for pseudophakic cystoid macular edema in patients with diabetes. J. Cataract. Refract. Surg. 2017, 43, 1376–1382. [Google Scholar] [CrossRef]
- Reichel, E. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am. J. Ophthalmol. 2009, 148, 128–135.e2. [Google Scholar]
- Schaub, F.; Adler, W.; Enders, P.; Koenig, M.C.; Koch, K.R.; Cursiefen, C.; Kirchhof, B.; Heindl, L.M. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefes Arch. Clin. Exp. Ophthalmol. 2018, 256, 909–917. [Google Scholar] [CrossRef]
- Tranos, P.G.; Wickremasinghe, S.S.; Stangos, N.T.; Topouzis, F.; Tsinopoulos, I.; Pavesio, C.E. Macular edema. Surv. Ophthalmol. 2004, 49, 470–490. [Google Scholar] [CrossRef]
- Makri, O.E.; Tsapardoni, F.N.; Plotas, P.; Ifantis, N.; Xanthopoulou, P.T.; Georgakopoulos, C.D. Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: Case report and review of the literature. BMC Res. Notes 2017, 10, 127. [Google Scholar] [CrossRef] [PubMed]
- Do, J.R.; Oh, J.-H.; Chuck, R.S.; Park, C.Y. Transient corneal edema is a predictive factor for pseudophakic cystoid macular edema after uncomplicated cataract surgery. Korean J. Ophthalmol. 2015, 29, 14–22. [Google Scholar] [CrossRef] [PubMed]
- Barone, A.; Russo, V.; Prascina, F.; Noci, N.D. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 2009, 29, 33–37. [Google Scholar] [CrossRef] [PubMed]
- Spitzer, M.S.; Ziemssen, F.; Yoeruek, E.; Petermeier, K.; Aisenbrey, S.; Szurman, P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J. Cataract. Refract. Surg. 2008, 34, 70–75. [Google Scholar] [CrossRef]
- Kakkassery, V.; Schultz, T.; Wunderlich, M.I.; Schargus, M.; Dick, H.B.; Rehrmann, J. Evaluation of predictive factors for successful intravitreal dexamethasone in pseudophakic cystoid macular edema. J. Ophthalmol. 2017, 2017, 4625730. [Google Scholar] [CrossRef]
- Altintas, A.G.K.; Ilhan, C. Intravitreal dexamethasone implantation in intravitreal bevacizumab treatment-resistant pseudophakic cystoid macular edema. Korean J. Ophthalmol. 2019, 33, 259–266. [Google Scholar] [CrossRef]
- Conway, M.D.; Canakis, C.; Livir-Rallatos, C.; Peyman, G.A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J. Cataract. Refract. Surg. 2003, 29, 27–33. [Google Scholar] [CrossRef]
- Koutsandrea, C.; Moschos, M.M.; Brouzas, D.; Loukianou, E.; Apostolopoulos, M.; Moschos, M. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema. Retina 2007, 27, 159–164. [Google Scholar] [CrossRef]
- Mylonas, G.; Georgopoulos, M.; Malamos, P.; Georgalas, I.; Koutsandrea, C.; Brouzas, D.; Sacu, S.; Perisanidis, C.; Schmidt-Erfurth, U. Comparison of dexamethasone intravitreal implant with conventional triamcinolone in patients with postoperative cystoid macular edema. Curr. Eye Res. 2016, 42, 648–652. [Google Scholar] [CrossRef]
- Benhamou, N.; Massin, P.; Haouchine, B.; Audren, F.; Tadayoni, R.; Gaudric, A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am. J. Ophthalmol. 2003, 135, 246–249. [Google Scholar] [CrossRef]
- Boscia, F.; Furino, C.; Dammacco, R.; Ferreri, P.; Sborgia, L.; Sborgia, C. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: Functional and anatomic results. Eur. J. Ophthalmol. 2005, 15, 89–95. [Google Scholar] [CrossRef] [PubMed]
- Dang, Y.; Mu, Y.; Li, L.; Mu, Y.; Liu, S.; Zhang, C.; Zhu, Y.; Xu, Y. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des. Dev. Ther. 2014, 8, 1441–1449. [Google Scholar] [CrossRef]
- Lindholm, J.-M.; Taipale, C.; Ylinen, P.; Tuuminen, R. Perioperative subconjunctival triamcinolone acetonide injection for prevention of inflammation and macular oedema after cataract surgery. Acta Ophthalmol. 2019, 98, 36–42. [Google Scholar] [CrossRef] [PubMed]
- Han, J.V.; Patel, D.V.; Squirrell, D.; McGhee, C.N. Cystoid macular oedema following cataract surgery: A review. Clin. Exp. Ophthalmol. 2019, 47, 346–356. [Google Scholar] [CrossRef]
- Wielders, L.H.; Schouten, J.S.; Winkens, B.; Biggelaar, F.J.V.D.; Veldhuizen, C.A.; Murta, J.N.; Goslings, W.R.; Kohnen, T.; Tassignon, M.-J.; Joosse, M.V.; et al. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED study report. J. Cataract. Refract. Surg. 2018, 44, 836–847. [Google Scholar] [CrossRef]
- Ylinen, P.; Holmström, E.; Laine, I.; Lindholm, J.-M.; Tuuminen, R. Anti-inflammatory medication following cataract surgery: A randomized trial between preservative-free dexamethasone, diclofenac and their combination. Acta Ophthalmol. 2018, 96, 486–493. [Google Scholar] [CrossRef]
- Ylinen, P.; Taipale, C.; Lindholm, J.-M.; Laine, I.; Holmström, E.; Tuuminen, R. Postoperative management in cataract surgery: Nepafenac and preservative-free diclofenac compared. Acta Ophthalmol. 2018, 96, 853–859. [Google Scholar] [CrossRef]
- Danni, R.; Viljanen, A.; Aaronson, A.; Tuuminen, R. Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac. Acta Ophthalmol. 2019, 97, 589–595. [Google Scholar] [CrossRef]
- Ilveskoski, L.; Taipale, C.; Tuuminen, R. Anti-inflammatory medication of cataract surgery in pseudoexfoliation syndrome—NSAID is needed. Curr. Eye Res. 2019, 45, 814–819. [Google Scholar] [CrossRef]
- Yonekawa, Y.; Kim, I.K. Pseudophakic cystoid macular edema. Curr. Opin. Ophthalmol. 2012, 23, 26–32. [Google Scholar] [CrossRef] [PubMed]
- Wielders, L.H.; Lambermont, V.A.; Schouten, J.S.; Biggelaar, F.J.V.D.; Worthy, G.; Simons, R.W.; Winkens, B.; Nuijts, R.M.M.A.; Schouten, J. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: A systematic review and meta-analysis. Am. J. Ophthalmol. 2015, 160, 968–981.e33. [Google Scholar] [CrossRef] [PubMed]
- Wielders, L.H.; Schouten, J.S.; Winkens, B.; Biggelaar, F.J.V.D.; Veldhuizen, C.A.; Findl, O.; Murta, J.N.; Goslings, W.R.; Tassignon, M.-J.; Joosse, M.V.; et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report. J. Cataract. Refract. Surg. 2018, 44, 429–439. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.J. Re: Kessel et al.: Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops (Ophthalmology 2014;121:1915–24). Ophthalmology 2015, 122, e34–e35. [Google Scholar] [CrossRef]
- Grzybowski, A. Re: Kessel et al.: Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: A systematic review (Ophthalmology 2014;121:1915–24). Ophthalmology 2015, 122, e16–e17. [Google Scholar] [CrossRef]
- Arevalo, J.F.; Maia, M.; Garcia-Amaris, R.A.; Roca, J.A.; Sanchez, J.G.; Berrocal, M.H.; Wu, L. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema. Ophthalmology 2009, 116, 1481–1487.e1. [Google Scholar] [CrossRef]
- La Rosa, A.G.-D.; Navarro-Partida, J.; Altamirano-Vallejo, J.C.; Hernandez-Gamez, A.G.; Garcia-Bañuelos, J.J.; Armendariz-Borunda, J.; Santos, A. Novel triamcinolone acetonide-loaded liposomes topical formulation for the treatment of cystoid macular edema after cataract surgery: A pilot study. J. Ocul. Pharmacol. Ther. 2019, 35, 106–115. [Google Scholar] [CrossRef]
- Maleki, A.; Aghaei, H.; Lee, S. Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema. Am. J. Ophthalmol. Case Rep. 2018, 10, 203–205. [Google Scholar] [CrossRef]
- Dimopoulos, S.; Deuter, C.M.E.; Blumenstock, G.; Zierhut, M.; Dimopoulou, A.; Voykov, B.; Bartz-Schmidt, K.-U.; Doycheva, D. Interferon alpha for refractory pseudophakic cystoid macular edema (irvine-gass syndrome). Ocul. Immunol. Inflamm. 2019, 28, 315–321. [Google Scholar] [CrossRef]
- Wu, L.; Arevalo, J.F.; Hernandez-Bogantes, E.; Roca, J.A. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: Results of the pan-American collaborative retina study group. Int. Ophthalmol. 2012, 32, 235–243. [Google Scholar] [CrossRef]
- Ersoy, L.; Caramoy, A.; Ristau, T.; Kirchhof, B.; Fauser, S. Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. Br. J. Ophthalmol. 2013, 97, 862–865. [Google Scholar] [CrossRef] [PubMed]
N = 536 Eyes (of 536 Patients) | |
---|---|
PCME criteria: No pre-existing ME on preoperative OCT | |
PCME classification | |
GR 0a = no retinal thickening (CSMT < 10%, no signs of ME) | N = 498 (93%) |
GR 0b = retinal thickening without ME (CSMT ≥ 10%, no signs of ME) | N = 19 (3.5%) |
GR I = subc. PCME (CSMT ≥ 10% at any postoperative timepoint + ME) | ≥GR I N = 19 (3.5%) |
GR II = acute PCME (GR I + expected CDVA deterioration) | ≥GR II N = 13 (2.4%) |
GR III = l-s PCME (GR II + no ME resolution within 2 mo/with topical meds) | GR III N = 1 (0.2%) |
Gr 0 | ≥GR I | ≥Gr II | =GR III | |
---|---|---|---|---|
No ME | Subclinical PCME | Acute PCME | Long-Standing PCME | |
Age (years) | 76.1 ± 6.7 | 76.4 ± 7.1 | 77.2 ± 7.6 | 77 |
Male:Female (%) | 35:65 | 36:64 | 56:44 | 1:0 |
Operation time (min) | 19.1 ± 9.1 | 20.5 ± 8.6 | 22.2 ± 8.9 | 22 |
Phacoenergy (CDE) | 19.9 ± 10.6 | 23.0 ± 11.5 | 22.8 ± 11.8 | 31.88 |
Aqueous flare (pu/ms) | 9.7 ± 8.0 | 11.4 ± 8.1 | 9.6 ± 5.8 | 6.3 |
CSMT (μm) | 273.5 ± 32.4 | 274.4 ± 34.9 | 286.9 ± 42.2 | 312 |
CDVA (decimals) | 0.36 ± 0.17 | 0.35 ± 0.14 | 0.35 ± 0.16 | CF |
IOP (mmHg) | 15.8 ± 4.0 | 14.5 ± 3.9 | 14.1 ± 4.5 | 10 |
Gr 0 | ≥GR I | ≥Gr II | =GR III | |
---|---|---|---|---|
No ME | Subclinical PCME | Acute PCME | Long-Standing PCME | |
Aqueous flare (pu/ms) | ||||
change at 28 days | +4.9 ± 15.5 | +8.4 ± 9.8 | +10.1 ± 9.9 * | +29.2 |
CSMT (μm) | ||||
change at 28 days | +4.0 ± 22.1 | +98.1 ± 95.7 † | +129.9 ± 99.3 † | +155 |
CDVA (decimals) | ||||
at 28 days | 0.87 ± 0.29 | 0.74 ± 0.27 * | 0.64 ± 0.18 * | 0.50 |
IOP (mmHg) | ||||
at 28 days | 10.6 ± 2.8 | 11.0 ± 3.2 | 10.7 ± 3.5 | 8 |
Gr 0 | ≥GR I | ≥Gr II | =GR III | |
---|---|---|---|---|
No ME | Subclinical PCME | Acute PCME | Long-Standing PCME | |
Foveal thickness | ||||
at 28 days (m) | 247.5 ± 60.6 | 286.0 ± 138.6 | 327.8 ± 155.7 | 439 |
change at 28 days (m) | 6.36 ± 49.6 | 45.2 ± 109.5 | 83.0 ± 130.8 * | 228 |
change at 28 days (%) | 3.76 ± 23.3 | 16.8 ± 44.1 | 33.3 ± 55.4 * | 108.1 |
CRT max | ||||
at 28 days (m) | 332.6 ± 68.7 | 364.5 ± 105.7 | 406.8 ± 136.4 | 612 |
change at 28 days (m) | 9.6 ± 60.7 | 41.2 ± 76.5 | 78.6 ± 118.8 * | 314 |
change at 28 days (%) | 3.16 ± 18.8 | 11.5 ± 20.8* | 23.4 ± 37.0 * | 105.4 |
Parafoveal thickness | ||||
at 28 days (m) | 333.1 ± 29.0 | 333.6 ± 54.7 | 347.1 ± 54.5 | 426 |
change at 28 days (m) | 7.54 ± 19.6 | 4.29 ± 36.2 | 17.2 ± 27.1 | 37.5 |
change at 28 days (%) | 2.32 ± 6.02 | 0.96 ± 10.6 | 4.82 ± 7.41 | 9.66 |
Perifoveal thickness | ||||
at 28 days (m) | 291.5 ± 20.2 | 293.0 ± 25.4 | 291.2 ± 27.7 | 339.7 |
change at 28 days (m) | 5.50 ± 15.7 | 4.71 ± 9.42 | 8.37 ± 4.58 | 10.4 |
change at 28 days (%) | 2.01 ± 4.96 | 1.69 ± 2.98 | 2.94 ± 1.53 | 3.16 |
Gr 0 | ≥GR I | ≥Gr II | =GR III | |
---|---|---|---|---|
No ME | Subclinical PCME | Acute PCME | Long-Standing PCME | |
Operation time (min) | 18.9 ± 8.8 | 22.1 ± 8.7 | 21.9 ± 9.2 | 22 |
Phacoenergy (C.D.E.) | 20.2 ± 11.0 | 23.2 ± 11.6 | 21.2 ± 10.9 | 31.88 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aaronson, A.; Achiron, A.; Tuuminen, R. Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac. J. Clin. Med. 2020, 9, 3034. https://doi.org/10.3390/jcm9093034
Aaronson A, Achiron A, Tuuminen R. Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac. Journal of Clinical Medicine. 2020; 9(9):3034. https://doi.org/10.3390/jcm9093034
Chicago/Turabian StyleAaronson, Alexander, Asaf Achiron, and Raimo Tuuminen. 2020. "Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac" Journal of Clinical Medicine 9, no. 9: 3034. https://doi.org/10.3390/jcm9093034